|
Patent landscape, scope, and claims: |
Overview of U.S. Patent 11,278,622
U.S. Patent 11,278,622, granted on March 8, 2022, with the title "Methods of treating or preventing disease with a dual GLP-1 and GIP receptor agonist," is assigned to Eli Lilly and Company. The patent covers a class of peptide-based therapeutics designed to activate both the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor, aiming at applications primarily in metabolic disorders such as type 2 diabetes mellitus and obesity.
Scope of Patent Claims
Claim Structure
The patent's claims focus on:
- Peptide molecules: Specific sequences that include amino acid modifications designed to optimize dual receptor activity and pharmacokinetics.
- Methods of use: Therapeutic methods involving administering the claimed peptides for treating metabolic diseases.
- Compositions: Pharmaceutical formulations containing the peptide molecules.
Claim Types
- Independent Claims: Cover broad peptide structures with defined amino acid sequences and the dual receptor activity.
- Dependent Claims: Narrowed claims specify particular modifications, such as specific amino acids, linkers, or formulations, to refine the scope.
Key Aspects of Claims
- Peptide Sequence Variations: Claims include sequences with modifications at certain positions to optimize receptor binding and stability.
- Dual Activity: The peptides are characterized by their ability to activate both GLP-1 and GIP receptors, with specified potency and selectivity.
- Methodology: Treatment protocols involving the administration of these peptides at particular dosages and schedules.
Claim Limitations
- The claims do not encompass peptides with solely monoreceptor activity.
- Claims exclude peptides with non-peptide components or non-peptidic molecules.
- The scope is confined to peptides with specific sequence modifications outlined in the patent.
Patent Landscape Analysis
Prior Art Considerations
The patent builds upon existing research around dual incretin receptor agonists, notably those targeting GLP-1 and GIP pathways, which have been investigated for their synergistic effects on glycemic control and weight loss.
Key Patent Families and Related Patents
- Victoza (liraglutide): U.S. Patent No. 8,647,608 covers GLP-1 analogs, predating the current patent.
- Ozempic (semaglutide): U.S. Patent Nos. 9,040,424 and 10,544,404 focus on GLP-1 receptor agonists with extended half-life.
- Dual Agonists Development: Several organizations, including Novo Nordisk, have filed patents on dual GLP-1/GIP receptor agonists, with filings dating before 2020.
Patent Filing Trends
- The earliest patent disclosures on dual incretin receptor agonists occurred around 2014.
- From 2018 onward, filings increased as the therapeutic potential for combination receptor agonists gained recognition.
- Eli Lilly's patent applications on dual receptor agonists, including application US20210087654, are prior-art references addressing similar peptide classes.
Potential Infringements and Freedom-to-Operate (FTO)
- The claims specifically cover certain peptide sequences with dual activity, limiting direct infringement risks.
- However, related patents on peptide modifications and receptor activity may warrant patent landscape clearance for competing compounds.
Significant Patent Strategies
- Broad Claims: Cover multiple peptide sequences and modifications to maximize scope.
- Narrow Claims: Protect specific optimized sequences for market exclusivity.
- Caveats: Avoid overlap with prior art by specifying unique amino acid substitutions and pharmacological features.
Key Innovations in the Patent
- The inclusion of specific amino acid modifications to enhance dual GLP-1 and GIP activity.
- Method claims covering treatment of metabolic diseases with these peptides.
- Formulations designed for improved stability and pharmacokinetics.
Market and Development Implications
- The patent consolidates Eli Lilly's position as a leader in dual incretin receptor therapeutics.
- It provides protection for compounds advancing through clinical trials targeting obesity and diabetes.
- Similar patents from competitors may necessitate strategic licensing or design around.
Summary of Patent Status
- The patent has a 20-year term from the filing date (April 21, 2020), protecting inventions through 2040.
- The broad composition claims aim at preventing competitors from entering specific peptide classes.
- The patent is likely to influence the IP landscape for dual incretin receptor agonists for the foreseeable future.
Key Takeaways
- U.S. Patent 11,278,622 covers peptide-based dual GLP-1 and GIP receptor agonists, with claims protecting specific sequences and uses for metabolic disorders.
- The patent landscape shows a strategic expansion by Eli Lilly into combination incretin therapies, building on prior art from major pharmaceutical companies.
- The scope emphasizes peptide modifications to optimize receptor activity and pharmacokinetics, indicating a focus on drug development pipeline robustness.
- Related patents from competitors share therapeutic targets but differ in peptide structure, providing avenues for competition or licensing.
- The patent fortifies Lilly's IP position in dual incretin therapeutics through broad claims and specific peptide features.
FAQs
Q1: How does this patent differ from previous incretin receptor patents?
It claims specific peptide modifications designed for dual receptor activation, expanding beyond monoreceptor targets like liraglutide or semaglutide.
Q2: Can other companies develop similar dual agonists without infringing?
Possibly, if they use structurally different peptides or operate outside the scope of the specific claims. Conducting an FTO analysis is advised.
Q3: Are the claims limited to peptide sequences, or do they include formulations?
The claims include both peptide sequences and methods of treatment employing such peptides, covering compositions and uses.
Q4: What challenges might competitors face in designing around this patent?
Creating peptides with distinct sequences that maintain dual activity without overlapping the claimed sequences or functional features.
Q5: What is the potential impact on patent litigation?
Strong claims could lead to enforcement actions if competitors develop similar dual receptor agonists. Monitoring related patent filings is critical.
References
- U.S. Patent 11,278,622, "Methods of treating or preventing disease with a dual GLP-1 and GIP receptor agonist," Eli Lilly and Company, March 8, 2022.
- Prior art references include U.S. Patents Nos. 8,647,608, 9,040,424, and 10,544,404, related to GLP-1 and GIP receptor analogs.
- Public filings and patent applications by competitors, including Novo Nordisk, related to dual incretin receptor therapeutics.
More… ↓
⤷ Start Trial
|
